Accrual from Cancer Treatment Protocols Conducted by Your Research Base Available for Use by CCOPs^{1, 2}

<u>Directions</u>: Column (3) Indicate pharmacologic phase as Phase I, II, III or Adjuvant.

Column (6) Indicate projected completion date based on current accrual rate, if applicable.

| (2) (3) | | (4) | | (6) | (7) Number of Patients/Credits Entered ^{1,2} | | | |
|---------------------------|------------------------|----------------------------------|---|---------------------------------------|---|--|--|--|
| NCI Protocol Number | Pharmacologic Phase | Disease Site | Date Opened | Projected Completion Date | 7/1/03 thru 6/30/04 patients/credit | Total Since Opened patients/credits | | |
| | | | | | 1 | I | | |
| | | | | | 1 | | | |
| | | | | | , | I | | |
| | | | | | , | | | |
| | | | | | , | | | |
| | | | | | , | | | |
| | NCI Protocol | NCI Pharmacologic Protocol Phase | NCI Pharmacologic Disease Protocol Phase Site | NCI Pharmacologic Disease Date Opened | NCI Pharmacologic Disease Date Projected Opened Completion | (2) (3) (4) (5) (6) Number of Pa Enter NCI Pharmacologic Phase Site Opened Completion patients/credit | | |

| Total: | 1 | 1 |
|--------|---|---|

¹Competing continuation applicants should only count patients/credits entered through the CCOPs, not through Members/Affiliates.

² New applicants may report members= activity, since CCOPs were not available.

Accrual from Cancer Prevention and Control Protocols Approved at your Research Base Available for Use by CCOPs, Members/Affiliates, and other Research Base Members/Affiliates (if for Intergroup Studies)^{1,2}

(List only protocols approved by the DCP Cancer Prevention and Control Protocol Review Committee³. In Column (5) indicate projected completion date based on current accrual rate, if applicable. <u>Do not include protocols grandfathered in.)</u>

| | | | | | | (7) Number of Subjects/Credits Entered | | | | | | | | | | | | | | | | |
|---|--------------------|----------------|-----------------|------------------|---------------|--|---------------------------|---------------------------|---------------------------|---------------------------|---|--------------------|--------------------|--------------------|--|--------------|-----------------------------|-----------------|-----------------------------|-----------------|-----------------------------|-----------------|
| | | | | | | cco |)P⁴ | Member | /Affiliate | Intergrou Other RE | p Studies ^{1, 2} B Mem/Affil* | | | | | | | | | | | |
| (1) Protocol Title ⁵ | (2) | (3) Target | (4) Date Opened | (5) Projected | (6) Credit | 7/1/03 thru 6/30/04 | Total* Since Opened | 7/1/03 thru 6/30/04 | Total* Since Opened | 7/1/03 thru 6/30/04 | Total* Since Opened | | | | | | | | | | | |
| (Precede with an * if Intergroup Protocol) | Protocol Number | Sample Size | Date | | | d Completion | Completion Date | Date Date | Completion Date | Completion Date | Completion Date | Completion Date | Completion Date | Completion Date | | Per Entry | (a) subjects/ credits | (b) subjects | (c) subjects /credits | (d) subjects | (e) subjects /credits | (f) subjects |
| | | | | | | I | | 1 | | I | | | | | | | | | | | | |
| | | | | | | 1 | | 1 | | I | | | | | | | | | | | | |
| | | | | | | 1 | | 1 | | I | | | | | | | | | | | | |
| | | | | | | 1 | | 1 | | I | | | | | | | | | | | | |
| | 1 | | | | | Subj/Credits | Subjects | Subj/Credit | s Subjects | Subj/Credits | Subjects | | | | | | | | | | | |

| Grand Total Crodits 7/1/03-6/30/04: | [Add cradits in columns 7(a) 7(c) and 7(a)] |
|-------------------------------------|---|
| Column Total for Table 2a:/ | |

Include only Intergroup studies where you have role as data coordinating center.

Do not include Intergroup studies from other Research Bases.

³ Other than DCP-approved protocols may be listed if new applicant.

⁴ For DCP approved protocols with credit assigned to CCOPs only, enter the number of participants and zero (0) credits

⁵ Provide copies of any abstracts/manuscripts related to the protocols listed above.

Accrual from Cancer Prevention and Control Protocols Sponsored by <u>other CCOP Research Bases</u> (Intergroup) for Use by Your Members/Affiliates.

(List only protocols approved by the DCP Cancer Prevention and Control Protocol Review Committee.)
In Column (5) indicate projected completion date based on current accrual rate, if applicable. Do not include protocols grandfathered in.)

| (1) | (2) NCI | (3) Target | (4) | (5) | Number of S Membe | 6) bjects Entered r/Affiliate | |
|--------------------------------|--------------------|----------------|--------|--------------------|---------------------------|-------------------------------------|--|
| Protocol ¹ Title | Protocol Number | Sample Size | Opened | Completion Date | 7/1/03 thru 6/30/04 | Total Since Opened | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

¹ Provide copies of any abstracts/manuscripts related to the protocols listed above.

Participation in Cancer Prevention and Control Research Studies Sponsored by other Federally Funded Mechanisms (e.g., research project grant (R01), contract).

Directions: If applicable, provide the following information regarding the Research Base=s participation in cancer prevention and control research studies supported by other federally funded mechanisms. Column

- Indicate the Federally Funded Mechanism (e.g., Grant or Contract Number) (1)
- Provide Title of the Study. Designate as either (C)= Currently Active; and/or (P) = Planned for Proposed Funding Period. (2)
- (3)Briefly describe primary involvement/participation in the research study
- (4) Provide number of participants accrued for the period July 1, 2003 through June 30, 2004.
- Provide projected number of participants for proposed funding period. (5)

| (1) Federal Administrative & Funding Instrument e.g. R01CA12345, N01CN12345 | (2) Title of the Research Study <u>Designate as either</u> : (C) Currently Active; and/or (P) Planned for Proposed Funding Period | (3) Primary Involvement in Research Study ** Indicate relationship of participants that apply: CCOP; cooperative group affiliate program; affiliate, member. | (4) Number of Participan ts accrued (7/03-6/04) | (5) Number of Proposed Participant Accruals |
|---|---|--|---|---|
| Example: R01CA11111 | (C) Home Care Training for Breast Cancer Patients | Coordinate access to affiliated CCOPs to the research study | 15 | |
| Example: N01CN12345 | (P) Phase II Trial DFMO in Cervix | RB member institution accrues to research study | N/A | 20 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

^{**} Narrative explanation may be attached if needed to fully document your experience.

Cancer Prevention and Control Concepts Approved by NCI for Protocol Development (List only concepts approved by the DCP Cancer Prevention and Control Concept Review Committee since June 1, 2003.) ¹

<u>Directions</u>: Column (5) indicate projected completion date based on current accrual rate, if applicable.

| (1) Concept | | Projected | (5) | Estimated A | (6) nnual Accrual njects) | |
|----------------|--------|-------------|--------------------|-------------------------|---------------------------------|----------------------|
| 91711 | Number | Sample Size | Submission Date | Duration of Study | CCOP | Member/ Affiliate |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Total:

¹Other than DCP-approved protocols may be listed by <u>new applicants</u>.

| (1) | (2) | (3) | (4) | (5) |
|------------------|----------------------|--|--------------------------------------|-------------------------|
| Concept Title | Target Population | Projected Concept Submission Date | Projected Duration of Study | Total Sample Size |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

CCOP Affiliations

Directions: Please include copies of signed Affiliation Agreements between the research base and each CCOP

| (1) | (2) | (5) Projected Annual Accrual | | | | | |
|-----------|--|------------------------------|---------|--------------|-------------------|--|--|
| CCOP Name | | Tre | atment | Cancer Preve | ntion and Control | | |
| | Full Name of Principal Investigator | Patients | Credits | Subjects | Credits | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Total: | ITV · | 1 [CC: | |
|---------|-------|--------|--|
| ı Olai. | IIA. | 1100. | |
| | | | |

Member/Affiliate Participation in NCI Approved Cancer Prevention and Control

| (1) | (2) | (3) | (4) Projected Annual Accrual Protocols approved at your RB only | | | |
|-----------------------|--|------------------------------|---|---------|--|--|
| Member/Affiliate Name | Full Name of Principal Investigator | Location City, State, Zip | Subjects | Credits | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Total: ————

"Prevention Members"

Please list the cooperative group members, affiliate programs and/or cancer center affiliates other than CCOPs that are included in the application as APrevention Members.@

Indicate with a (X) which of the following activities the "Prevention Member" contributes to in a significant way relative to the goals of the Research Base.

- (4) Substantial accrual to chemoprevention studies
- (5) Leadership in study implementation and management
- (6) Scientific leadership in the development of prevention clinical trials
- (7) Active membership in research base cancer prevention committees
- (8) Conduct of preclinical studies and/or Phase I and II clinical trials necessary for drug development
- (9) Conduct of correlative research, such as that related to mechanisms of action, biomarkers, molecular targets, etc.

Include a proposal for each APrevention Member@ that describes how the member will contribute to the goals of the research base related to cancer prevention (See RFA Application Procedures, 2. Research Base Applicants, d. last paragraph). A separate budget must be provided for each Aprevention member.@

| (1) | (2) | (2) | Areas of Significant Contribution | | | | | | |
|-----------------------|--|-----|-----------------------------------|-----|-----|-----|-----|-----|--|
| Member/Affiliate Name | (2) (3) ate Name Full Name of Principal Investigator City, State, Zip | | (4) | (5) | (6) | (7) | (8) | (9) | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

Reporting On-Site Auditing Activities for Cancer Prevention Trials, Large-scale e.g., (STAR), and Others, <u>if applicable</u>

<u>For Large-scale Prevention Trials</u>, e.g., the Study of Tamoxifen and Raloxifene (STAR), provide a list of ALL the participating institutions along with the audit schedule (MUST be provided) using the Table Format below.

<u>For Other Prevention Trials</u> that include participating Institutions other than Cooperative Group Treatment Trial institutions, provide a list of only these other institutions with their Audit Schedule using the Table Format below.

| Instit.# | Name | Parent | Membership Date | Current Status (Active/Term- inated | Accrual ——* | Accrual ——* | Accrual ———* | Accrual Projected for upcoming year* | Date of last Audit | Date of Next proposed audit |
|----------|------|--------|--------------------|---|----------------|----------------|-----------------|---|-----------------------|--------------------------------------|
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |

^{*}Fill in accrual blank with year (this should cover the preceding 36 months (e.g., 2001, 2002, 2003), if applicable.